Biotechnology

Gainers ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland. Altamira Therapeutics Ltd. (NASDAQ: CYTO) shares jumped 52.7% to $3.59 after the company said data from a...

U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session. Ardelyx, Inc. (NASDAQ: ARDX) gained 28% to $3.70 after the company reported better-than-expected Q4 sales results. C3.ai, Inc. (NYSE: AI) shares...

Moleculin Biotech Inc (NASDAQ: MBRX) announced the topline results from its MB-105 European Phase 1 clinical trial assessing the safety and efficacy of Annamycin as a single agent for relapsed or refractory acute myeloid leukemia (AML).  The final MB-105 results align with the...

Neurocrine Biosciences Inc (NASDAQ: NBIX) and Voyager Therapeutics Inc (NASDAQ: VYGR) have formed a new strategic collaboration to advance multiple gene therapies for neurological diseases.  Voyager will receive up-front consideration of $175 million, including a $39...

The most overbought stocks in the information technology sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock...

Oppenheimer cut CarMax, Inc. (NYSE: KMX) price target from $100 to $75. . Oppenheimer analyst Brian Nagel maintained an Outperform rating on the stock. CarMax shares fell 1.3% to $56.47 in pre-market trading. JP Morgan cut Paychex, Inc. (NASDAQ: PAYX) price target from $121 to $119. JP Morgan...

Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) announced the topline results of RELIEF-PHN-1 Phase 2 proof-of-concept study of LX9211 in postherpetic neuralgia, a lasting pain in the areas of the skin that had shingles. LX9211 achieved a reduction in average daily pain score (ADPS) of 2.42 from...

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. Westrock Coffee Company, LLC (NASDAQ: WEST) shares tumbled 10.9% to $11.90 in pre-market trading after gaining 10% on Wednesday. Lexicon Pharmaceuticals, Inc. (...

Credit Suisse initiated coverage on OmniAb Inc (NASDAQ: OABI) with an Outperform rating and a price target of $13. The company is spun off of Ligand Pharmaceuticals Inc's (NASDAQ: LGND) antibody discovery business. The analyst says the company is the industry'...

Moleculin Biotech Inc (NASDAQ: MBRX) provided an update on its clinical programs evaluating Annamycin for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.  The data exhibited an 80% overall response rate (ORR) in the final...

At its Investor and Analyst Day event, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided an overview of Ligand's corporate structure and business following the successful spin-off of its OmniAb antibody discovery business. Management also introduced 2023 financial...

Luna Innovations Inc (NASDAQ: LUNA) has extended its existing relationship with Northrop Grumman Corp (NYSE: NOC) by bagging a new multi-year, multi-million-dollar agreement. The agreement includes an initial receipt of an over $3 million incremental, multi-unit purchase order...

Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104 did not meet its primary endpoint in the Phase 2 STEAMBOAT study compared to placebo in pediatric patients with epileptic encephalopathy with continuous spike-and-wave during sleep (EE-CSWS).  The primary endpoint was a...

The Dow Jones closed lower by around 500 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider...

Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years.  But as exciting as the new treatments and technology coming out of the sector can be, there’s even more experimental biotech that never sees the light of day. Between 2000 and...